Explore information regarding enrollment for the REACH CDM Study for Congenital Myotonic Dystrophy
REACH CDM: A clinical study for Congenital Myotonic Dystrophy (Congenital DM1)
Clinical research sites are open and seeking patients to participate in a Phase 3 clinical study for 6 months, testing a new medicine, for Congenital Myotonic Dystrophy (Congenital DM1).
If your child or loved one has Congenital DM1, they may be able to take part.
Patients who qualify to take part will receive study-related care at no cost. Travel assistance and reimbursement may be available.
- Is 6 to 16 years old
- Has Congenital DM1
- Can swallow, or take by a gastrostomy tube, liquid study medicine
There are additional requirements to qualify. See if your loved one qualifies.
About Congenital Myotonic Dystrophy (Congenital DM1)
Congenital Myotonic Dystrophy (Congenital DM1), also known as Steinert's disease, is a genetic disease and the most severe form of myotonic dystrophy. Symptoms of Congenital DM1 are present at birth and can include deformed feet and difficulties with breathing and feeding. Babies with Congenital DM1 are often called 'floppy' because the delay in the development of their muscles affects their ability to move. As children with Congenital DM1 grow up, the disease can affect many different parts of their body, leading to significant physical impairment and trouble with thinking.
- problems with thinking and problem solving;
- weakened muscles; and,
- speech, hearing and vision difficulties.
Frequently Asked Questions
What is a clinical study?
A clinical study is a type of research that studies a medicine given to people. They are done to see how safe and helpful tests and medicines are. Clinical studies need to be done for all new tests and medicines. When clinical studies find the test or medicine is safe and helpful, the test or medicine may be approved and then made available to all patients. Clinical studies must follow a set of strict rules to keep patients safe and make sure that the research is completely properly. A Phase 3 study is one used to allow decisions about whether the medicine can be approved for prescription. This type of study looks at whether the medicine is safe and helps with treatment by showing effectiveness against symptoms.
Why participate in a clinical study?
Choosing to participate in a clinical study is an important personal decision. Participation in a clinical study is voluntary. Below are a few reasons why people choose to take part in clinical research:
- To help future patients by contributing to research and science.
- To advance the understanding of a disease or condition.
- To support the effort to make a new medicine available to patients who need treatment.
- To gain access to potential new medicines before they become more widely available.
Will we be paid for taking part in this clinical study?
Patients in this study will not be paid. The study medicine and study related costs or procedures not considered part of standard care for someone with Congenital DM1 will be free of charge. Travel, accommodation and other out-of-pocket costs directly associated with attending study visits will be reimbursed.
Who should I contact for more information?
You can direct any questions you may have about the REACH CDM Study to:
Children's Hospital London Health Sciences Centre (LHSC), London, Ontario, Canada
Contact: Rhiannon Hicks 519-685-8441   firstname.lastname@example.org
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Contact: Emilie Hill Smith   613-737-7600 ext 4014   EHillSmith@cheo.on.ca
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Contact: Annette Guy   501-364-3380   email@example.com
Stanford University Palo Alto, California, United States
Contact: Stanford Neuromuscular Research   650-725 4341   firstname.lastname@example.org
University of Iowa Hospitals and Clinics, Iowa City, United States
Contact: Chandra Miller   319-384-9618   email@example.com
University of Rochester Medical Center, Rochester, New York, United States
Contact: James Hilbert   585-273-5590   james_hilbert@URMC.Rochester.edu
Contact: Jeanne Dekdebrun   585-276-4611   jeanne_Dekdebrun@URMC.Rochester.edu
Alternatively there is more information on the REACH CDM Study at: